Literature DB >> 25241069

In vivo mitochondrial inhibition alters corticostriatal synaptic function and the modulatory effects of neurotrophins.

E Mendoza1, J A Miranda-Barrientos1, R A Vázquez-Roque2, E Morales-Herrera2, A Ruelas1, G De la Rosa1, G Flores2, E Hernández-Echeagaray3.   

Abstract

Experimental evidence has revealed the role of mitochondria in various aspects of neuronal physiology. Mitochondrial failure results in alterations that underlie the pathogeneses of many neurodegenerative disorders, such as Parkinson's disease, Alzheimer's disease, Huntington's disease (HD) and amyotrophic lateral sclerosis. The mitochondrial toxin 3-nitropropionic acid (3-NP) has been used to model failure; for example, systemic administration of 3-NP imitates the striatal degeneration that is exhibited in the postmortem tissue of patients afflicted with HD. We have demonstrated that low, sub-chronic doses of 3-NP are sufficient to initiate the damage to striatal neurons that is associated with changes in neurotrophin expression levels. However, the mechanisms underlying the alterations in neuronal activity and neurotransmission due to 3-NP-induced mitochondrial dysfunction remain to be elucidated. In this paper, we focus on how corticostriatal transmission and its modulation by neurotrophins are altered in vivo after 5 days of mitochondrial inhibition with 3-NP. Recordings of population spikes and a paired pulse (PP) stimulation protocol were used to document changes in corticostriatal synapses in 3-NP-treated brain slices. The corticostriatal synapses were modulated by neurotrophins but displayed differential amplitude increases in the presence of brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), or neurotrophin-4/5 (NT-4/5) under control conditions. Neurotrophin-mediated synaptic modulation was decreased in slices from 3-NP-treated mice. The protein and mRNA levels of neurotrophins and their receptors were also modified in the 3-NP-treated tissue. Neuronal structural evaluation demonstrated that synaptic length and density were reduced in the 3-NP-treated mice, which partially explained the changes in the amplitudes of the synaptic field responses. Our results demonstrate that corticostriatal synapses are differentially modulated by neurotrophins and that this modulation is altered by mitochondrial failure. Mitochondrial dysfunction also affects neurotransmitter release in corticostriatal synapses, neurotrophin availability, dendritic arborization and the lengths of the striatal medium spiny neurons (MSNs).
Copyright © 2014 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  3-NP; dendrites; mitochondria; neurodegeneration; neurotrophins; striatum

Mesh:

Substances:

Year:  2014        PMID: 25241069     DOI: 10.1016/j.neuroscience.2014.09.018

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  12 in total

1.  Ca(2+) handling in isolated brain mitochondria and cultured neurons derived from the YAC128 mouse model of Huntington's disease.

Authors:  Jessica J Pellman; James Hamilton; Tatiana Brustovetsky; Nickolay Brustovetsky
Journal:  J Neurochem       Date:  2015-06-04       Impact factor: 5.372

2.  Neurotrophin-3 restores synaptic plasticity in the striatum of a mouse model of Huntington's disease.

Authors:  Victor G Gómez-Pineda; Francisco M Torres-Cruz; César I Vivar-Cortés; Elizabeth Hernández-Echeagaray
Journal:  CNS Neurosci Ther       Date:  2018-02-17       Impact factor: 5.243

3.  Dopamine regulation of striatal inhibitory transmission and plasticity: dopamine, low or high?

Authors:  Elizabeth Hernández-Echeagaray
Journal:  Neural Regen Res       Date:  2016-02       Impact factor: 5.135

Review 4.  Neuronal Plasticity: Neuronal Organization is Associated with Neurological Disorders.

Authors:  Yogesh Kumar Dhuriya; Divakar Sharma
Journal:  J Mol Neurosci       Date:  2020-06-06       Impact factor: 3.444

5.  Dopaminergic Modulation of Striatal Inhibitory Transmission and Long-Term Plasticity.

Authors:  Elizabeth Nieto Mendoza; Elizabeth Hernández Echeagaray
Journal:  Neural Plast       Date:  2015-07-29       Impact factor: 3.599

Review 6.  The association between PGC-1α and Alzheimer's disease.

Authors:  Gary Sweeney; Juhyun Song
Journal:  Anat Cell Biol       Date:  2016-03-28

Review 7.  Modulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington's Disease.

Authors:  Danielle A Simmons
Journal:  J Huntingtons Dis       Date:  2017

8.  Changes in PGC-1α/SIRT1 Signaling Impact on Mitochondrial Homeostasis in Amyloid-Beta Peptide Toxicity Model.

Authors:  Jessica D Panes; Pamela A Godoy; Tiare Silva-Grecchi; María T Celis; Oscar Ramirez-Molina; Javiera Gavilan; Carola Muñoz-Montecino; Patricio A Castro; Gustavo Moraga-Cid; Gonzalo E Yévenes; Leonardo Guzmán; Jeffrey L Salisbury; Eugenia Trushina; Jorge Fuentealba
Journal:  Front Pharmacol       Date:  2020-05-21       Impact factor: 5.810

Review 9.  Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First?

Authors:  Michela Zaltieri; Francesca Longhena; Marina Pizzi; Cristina Missale; PierFranco Spano; Arianna Bellucci
Journal:  Parkinsons Dis       Date:  2015-03-31

10.  NT-4/5 antagonizes the BDNF modulation of corticostriatal transmission: Role of the TrkB.T1 receptor.

Authors:  Francisco M Torres-Cruz; Israel César Vivar-Cortés; Isaac Moran; Ernesto Mendoza; Victor Gómez-Pineda; Francisco García-Sierra; Elizabeth Hernández-Echeagaray
Journal:  CNS Neurosci Ther       Date:  2019-01-21       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.